| Literature DB >> 30213875 |
Anna Chorzalska1, John Morgan2, Nagib Ahsan3,4, Diana O Treaba5, Adam J Olszewski6, Max Petersen1, Nathan Kingston1, Yan Cheng6, Kara Lombardo5, Christoph Schorl7, Xiaoqing Yu8, Roberta Zini9, Annalisa Pacilli10,11, Alexander Tepper1, Jillian Coburn3, Anita Hryniewicz-Jankowska12,13, Ting C Zhao14, Elena Oancea15, John L Reagan6, Olin Liang6, Leszek Kotula13, Peter J Quesenberry6, Philip A Gruppuso16, Rossella Manfredini9, Alessandro Maria Vannucchi10,11, Patrycja M Dubielecka1.
Abstract
Although the pathogenesis of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs) is linked to constitutive activation of the JAK-STAT pathway, JAK inhibitors have neither curative nor MPN-stem cell-eradicating potential, indicating that other targetable mechanisms are contributing to the pathophysiology of MPNs. We previously demonstrated that Abelson interactor 1 (Abi-1), a negative regulator of Abelson kinase 1, functions as a tumor suppressor. Here we present data showing that bone marrow-specific deletion of Abi1 in a novel mouse model leads to development of an MPN-like phenotype resembling human PMF. Abi1 loss resulted in a significant increase in the activity of the Src family kinases (SFKs), STAT3, and NF-κB signaling. We also observed impairment of hematopoietic stem cell self-renewal and fitness, as evidenced in noncompetitive and competitive bone marrow transplant experiments. CD34+ hematopoietic progenitors and granulocytes from patients with PMF showed decreased levels of ABI1 transcript as well as increased activity of SFKs, STAT3, and NF-κB. In aggregate, our data link the loss of Abi-1 function to hyperactive SFKs/STAT3/NF-κB signaling and suggest that this signaling axis may represent a regulatory module involved in the molecular pathophysiology of PMF.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30213875 PMCID: PMC6236464 DOI: 10.1182/blood-2018-05-848408
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113